Azacitidine Still Standard of Care in High-Risk MDS

A phase 2/3 study compared two combination approaches with azacitidine and concluded that azacitidine alone showed similar efficacy to either combo for patients with high-risk MDS. So what’s next in MDS management?
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply